Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.77 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.77 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.77 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049008 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18139902 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18141427 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18139257 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL1395457 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18139190 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18139237 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18140471 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18140643 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL18140502 | 1.00 | LPAR3 (0.77) | LPAR3LPAR2LPAR1LPAR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696877-B2 | Gel network hair treatment compositions with reduced odor | WELLA OPERATIONS US, LLC (US) | 2023-07-11 | — | — | US | claimed |
| CN-114790320-B | Low-viscosity high-strength acrylate rubber compound and preparation method thereof | 山东海益橡胶科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| EP-3290086-B1 | GEL NETWORK HAIR TREATMENT COMPOSITIONS WITH REDUCED ODOUR | WELLA OPERATIONS US LLC (US) | 2022-07-27 | — | — | EP | claimed |
| CN-114790320-A | Low-viscosity high-strength acrylate rubber compound and preparation method thereof | 山东海益橡胶科技有限公司 | 2022-07-26 | — | — | CN | claimed |
| EP-1305322-B1 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2010-01-13 | — | — | EP | claimed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| EP-4025675-B1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-12559611-B2 | Hydrophobic alginic acid particle group and method for producing same | NISSHINBO HOLDINGS INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20260041094-A1 | Compositions Comprising an Antimicrobial Boosting Agent | SYMRISE AG (DE) | 2026-02-12 | — | — | US | disclosed |
| US-20120164557-A1 | METHOD FOR PRODUCING A POLYMER ELECTROLYTE MEMBRANE | UBE INDUSTRIES, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-1855339-B1 | NOVEL POLYMER ELECTROLYTE, POLYMER ELECTROLYTE COMPOSITION, ELECTROLYTE MEMBRANE, AND PRODUCTION METHOD AND USE THEREOF | UBE INDUSTRIES (JP) | 2012-01-04 | — | — | EP | disclosed |
| EP-2362473-A1 | Novel polymer electrolyte, polymer electrolyte composition, electrolyte membrane, and production method and use thereof | Ube Industries, Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-2362472-A1 | Novel polymer electrolyte, polymer electrolyte composition, electrolyte membrane, and production method and use thereof | Ube Industries, Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-2355218-A1 | Novel polymer electrolyte, polymer electrolyte composition, electrolyte membrane, and production method and use thereof | Ube Industries, Ltd. (JP) | 2011-08-10 | — | — | EP | disclosed |
| EP-1305322-B1 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2010-01-13 | — | — | EP | disclosed |
| US-20080171252-A1 | Novel Polymer Electrolyte, Polymer Electrolyte Composition, Electrolyte Membrane, and Production Method and Use Thereof | UBE INDUSTRIES, LTD. (JP) | 2008-07-17 | — | — | US | disclosed |
| EP-1855339-A1 | NOVEL POLYMER ELECTROLYTE, POLYMER ELECTROLYTE COMPOSITION, ELECTROLYTE MEMBRANE, AND PRODUCTION METHOD AND USE THEREOF | Ube Industries, Ltd. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041094-A1 | Compositions Comprising an Antimicrobial Boosting Agent | TLR7, MYC, ERG28 | LPAR3 1611/4885LPAR2 1585/4885LPAR1 1623/4885 |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | RBP4, LRAT, RARB | LPAR3 508/4885LPAR2 668/4885LPAR1 709/4885 |
| US-12559611-B2 | Hydrophobic alginic acid particle group and method for producing same | ALG3, ALG1, HACD3 | LPAR3 365/4885LPAR2 319/4885LPAR1 564/4885 |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | LPAR3 1316/4885LPAR2 1270/4885LPAR1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.